Nussbaum Law Group, P.C. and Roberts Law Firm US, PC Announce A $50 Million Class Action Settlement with Pfizer on Behalf of Direct Purchasers of EpiPen® or Generic EpiPen

WHAT DOES THE SETTLEMENT PROVIDE?

A proposed settlement (“Settlement”) has been reached in a class action lawsuit with Pfizer, Inc., Meridian Medical Technologies, Inc., and King Pharmaceuticals, Inc. (n/k/a King Pharmaceuticals LLC) (together, “Pfizer”). Under the settlement, Pfizer agreed to pay $50,000,000 into a settlement fund for the Direct Purchaser Settlement Class (“Settlement Fund”). The lawsuit alleges that Defendants Mylan, N.V., Mylan Pharmaceuticals, Inc., and Mylan Specialty, LP (together, “Mylan”), and Pfizer entered into an illegal market allocation agreement with Teva Pharmaceuticals USA, Inc. that substantially delayed the launch of generic EpiPen and unlawfully extended Pfizer’s and Mylan’s monopoly over the epinephrine autoinjector market. The settlement does not resolve claims against Mylan, and the lawsuit against Mylan will continue until it is resolved. The Court has not decided who is right.

WHO IS INCLUDED?

People or entities who purchased EpiPen® or generic EpiPen directly from Mylan or Teva, for resale, at any time during the period from March 13, 2014, until the date on which the Court entered the Preliminary Approval Order, April 3, 2024.

Excluded from the Class are Defendants and their officers, directors, management, employees, predecessors, subsidiaries, and affiliates, and all federal governmental entities.

If you are a member of the Class, you must submit a claim form online at www.EpiPenDPPSettlement.com or by mail to get paid. This is the only way to receive a payment.

You may have received a claim form. If not, a claim form is available at www.EpiPenDPPSettlement.com. See the claim form for instructions on how to submit a claim. If the Court approves the Settlement, claims will be paid after any appeals are resolved.